Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | XIAP | P98170 | 1/20 | 0.35 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25424053 | 0.83 | ALDH1A1 (0.34) | CYP3A4MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL28964629 | 0.75 | KMT2A (0.45) | KMT2AHTR2CSIGMAR1ALDH1A1 | |
| SCHEMBL1190778 | 0.75 | KMT2A (0.45) | KMT2AHTR2CSIGMAR1ALDH1A1 | |
| SCHEMBL1191157 | 0.75 | KMT2A (0.45) | KMT2AHTR2CSIGMAR1ALDH1A1 | |
| SCHEMBL28482138 | 0.75 | LMNA (0.39) | CYP3A4MEN1KMT2ALMNAHSD17B10 | |
| SCHEMBL20320658 | 0.74 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1 | |
| SCHEMBL21825342 | 0.74 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1 | |
| SCHEMBL14881906 | 0.74 | ALDH1A1 (0.38) | MEN1KMT2AALDH1A1 | |
| SCHEMBL1717495 | 0.73 | ALDH1A1 (0.36) | CYP3A4MEN1KMT2ALMNAALDH1A1 | |
| SCHEMBL2905115 | 0.71 | HTR2C (0.52) | MEN1KMT2AHTR2CALDH1A1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | GLAXOSMITHKLINE LLC | 2013-02-21 | — | — | US | disclosed |
| US-7893056-B2 | Peptide deformylase inhibitors | GLAXOSMITHKLINE LLC (US) | 2011-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045962-A1 | PEPTIDE DEFORMYLASE INHIBITORS | PDF, DPEP1, DHPS | CYP3A4 3702/4885MEN1 2465/4885KMT2A 1907/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.